David Wheadon

David E.
Wheadon is Independent Chairman at Indivior Pharmaceuticals, Inc. since 2026.
Chairman at Indivior Ltd. since 2025.
Director at PSKW LLC since 2020.
Independent Non-Executive Director at Sotera Health Co. since 2021.
Independent Director at Vaxart, Inc. since 2021.
Independent Director at Seaport Therapeutics, Inc. since 2024.
Member of the American Psychiatric Association and the American Academy of Pharmaceutical Physicians.
Trustee at The Mount Sinai Health System, Inc. Formerly Director at Assertio Therapeutics, Inc. from 2019 to 2020.
Independent Director at ChemoCentryx, Inc. in 2022.
Director-Clinical Research at Smithkline Beecham Pharmaceuticals Ltd. from 1997 to 2000.
Director at Make-A-Wish Foundation of Illinois.
Director at Assertio Holdings, Inc. from 2019 to 2020.
Independent Director at Karuna Therapeutics, Inc. from 2020 to 2024.
Senior VP-Global Pharmaceutical Regulatory at Abbott Laboratories from 2005 to 2009.
Clinical Research Physician at Eli Lilly & Co. Senior Vice President-Global Regulatory Affairs at AstraZeneca PLC from 2014 to 2019.
Senior Vice President-US Regulatory Affairs at GSK Plc and GlaxoSmithKline Pharmaceuticals Ltd. from 2000 to 2005.
SVP-Global Regulatory Affairs & Patient Safety at AstraZeneca Pharmaceuticals LP from 2014 to 2019.
Executive Vice President-Research & Advocacy at JDRF International.
Senior VP-Scientific & Regulatory Affairs at Pharmaceutical Research & Manufacturers of America from 2009 to 2013.
Executive Vice President-Research & Advocacy at Juvenile Diabetes Research Foundation from 2013 to 2014.
Education includes undergraduate degree from Harvard College and doctorate from The Johns Hopkins University School of Medicine.